

Table 1. Patient characteristics by drug and dosage

Dosage (mg)	Apixaban (n = 140)		Rivaroxaban (n = 119)		Edoxaban (n = 70)	
	2.5 mg BID	5 mg BID	10 mg QD	15 mg QD	30 mg QD	60 mg QD
Male/female	35/26	58/21*	16/13	69/21*	21/24	24/1*
Number of patients	61	79	29	90	45	25
Total sampling number	78	105	40	122	89	48
Age, years	79.1 ± 5.8	70.9 ± 7.5*	73.1 ± 10.0	66.7 ± 10.0*	74.7 ± 9.5	66.5 ± 10.8
CHADS ₂ score	2.48 ± 0.92	1.87 ± 1.37*	1.94 ± 0.95 ⁺	1.34 ± 0.97*	1.61 ± 1.09 ^{+#}	1.60 ± 0.74
CHADS ₂ -VASc score	4.16 ± 1.27	3.06 ± 1.53*	3.41 ± 1.33 ⁺	2.40 ± 1.36*	2.61 ± 1.62 ^{+#}	2.67 ± 0.98
Height (cm)	155.9 ± 9.8	162.1 ± 8.8*	158.7 ± 10.7	164.7 ± 7.9*	154.6 ± 17.6	168.4 ± 7.3*
Weight (kg)	55.7 ± 10.6	62.8 ± 11.7*	60.3 ± 15.5 ⁺	67.3 ± 13.8* [×]	56.9 ± 13.8	72.9 ± 12.5* [×]
Cr (mg/dL)	0.97 ± 0.41	0.92 ± 0.27	0.94 ± 0.33	0.84 ± 0.19* [×]	0.85 ± 0.28 ⁺	0.84 ± 0.15 [×]
CCr (mL/min)	49.7 ± 17.4	68.4 ± 24.6*	64.0 ± 21.2 ⁺	84.4 ± 27.7* [×]	65.0 ± 31.6 ⁺	96.0 ± 37.7* [×]
AF/VTE	61/0	79/0	29/0	90/0	25/20	17/8

Notes:

CHADS₂, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke (double weight); CHA₂DS₂VASc, congestive heart failure, hypertension, age ≥ 75 years (double weight), diabetes mellitus, stroke (double weight), vascular disease, 74 > age ≥ 65 years, sex category (female); Cr, creatinine; CCr, creatinine clearance (Cockcroft–Gault formula); AF, atrial fibrillation; VTE, venous thromboembolism; QD, once daily; BID, twice daily; * p < 0.01 vs. low dose, ⁺ p < 0.01 vs. apixaban 2.5mg BID, [#] p < 0.01 vs. rivaroxaban 10mg QD, [×] p < 0.01 vs. Apixaban 5 mg BID, [§] p < 0.001 vs. Rivaroxaban 15 mg QD